Cardiac disease-free survival in patients with Thalassemia major treated with subcutaneous deferoxamine. An update of the Toronto Cohort

被引：0
|
作者：
机构：
来源：
| 1600年 / Publ by New York Acad of Sciences, New York, NY, USA卷 / 612期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] CARDIAC DISEASE FREE SURVIVAL IN PATIENTS WITH THALASSEMIA MAJOR TREATED WITH SUBCUTANEOUS DEFEROXAMINE - AN UPDATE OF THE TORONTO COHORT
    OLIVIERI, NF
    MCGEE, A
    LIU, P
    KOREN, G
    FREEDMAN, MH
    BENSON, L
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 612 : 585 - 586
  • [2] PREVENTION OF CARDIAC DISEASE BY SUBCUTANEOUS DEFEROXAMINE IN PATIENTS WITH THALASSEMIA MAJOR
    WOLFE, L
    OLIVIERI, N
    SALLAN, D
    COLAN, S
    ROSE, V
    PROPPER, R
    FREEDMAN, MH
    NATHAN, DG
    NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (25): : 1600 - 1603
  • [3] Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine
    Borgna-Pignatti, C
    Rugolotto, S
    De Stefano, P
    Zhao, HQ
    Cappellini, MD
    Del Vecchio, GC
    Romeo, MA
    Forni, GL
    Gamberini, MR
    Ghilardi, R
    Piga, A
    Cnaan, A
    HAEMATOLOGICA, 2004, 89 (10) : 1187 - 1193
  • [4] PROLONGED SURVIVAL IN PATIENTS WITH BETA-THALASSEMIA MAJOR TREATED WITH DEFEROXAMINE
    EHLERS, KH
    GIARDINA, PJ
    LESSER, ML
    ENGLE, MA
    HILGARTNER, MW
    JOURNAL OF PEDIATRICS, 1991, 118 (04): : 540 - 545
  • [5] Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis
    Piga, A
    Gaglioti, C
    Fogliacco, E
    Tricta, F
    HAEMATOLOGICA, 2003, 88 (05) : 489 - 496
  • [6] Phlebotomy and bolus subcutaneous deferoxamine in Algerian patients with thalassemia major or intermedia or sickle cell disease treated with hydroxyurea
    Bradai, Mohamed
    Bachir, Dora
    De Montalembert, Mariane
    BLOOD, 2007, 110 (11) : 20B - 21B
  • [7] Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major
    Borgna-Pignatti, C
    Cappellini, MD
    De Stefano, P
    Del Vecchio, GC
    Forni, GL
    Gamberini, MR
    Ghilardi, R
    Piga, A
    Romeo, MA
    Zhao, HQ
    Cnaan, A
    BLOOD, 2006, 107 (09) : 3733 - 3737
  • [8] Overall and disease-free survival in patients treated with CRS
    Fugazzola, Paola
    Coccolini, Federico
    Montori, Giulia
    Ceresoli, Marco
    Baggi, Paolo
    Costanzo, Antonio
    Tomasoni, Matteo
    Gregis, Francesco
    Nozza, Silvia
    Ansaloni, Luca
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) : 572 - 582
  • [9] Disease-free survival and the prognostic factors affecting disease-free survival in patients with medullary thyroid carcinoma: a multicenter cohort study
    Zuhur, Sayid Shafi
    Ozturk, Beyza Olcay
    Keskin, Umran
    Uysal, Serhat
    Hacioglu, Aysa
    Avci, Ugur
    Karsli, Seda
    Andac, Burak
    Ozbay, Umit Nur
    Kilinc, Faruk
    Erol, Selvinaz
    Catak, Merve
    Sodan, Hulyanur
    Pekkolay, Zafer
    Burhan, Sebnem
    Akbaba, Gulhan
    Ates, Coskun
    Yorulmaz, Goknur
    Tekin, Sakin
    Topcu, Birol
    Tuna, Mazhar Muslum
    Kadioglu, Pinar
    Gonen, Mustafa Sait
    Karaca, Zuleyha
    Ciftci, Sema
    Celik, Mehmet
    Guldiken, Sibel
    Tuzun, Dilek
    Altuntas, Yuksel
    Akturk, Mujde
    Niyazoglu, Mutlu
    Cinar, Nese
    Gul, Ozen Oz
    Kebapci, Medine Nur
    Akalin, Aysen
    Bayraktaroglu, Taner
    Elbuken, Gulsah
    ENDOCRINE, 2024, 85 (03) : 1300 - 1309
  • [10] RENAL ABNORMALITIES IN PATIENTS WITH BETA-THALASSEMIA MAJOR (BETA-TM) TREATED WITH CHRONIC SUBCUTANEOUS (SQ) DEFEROXAMINE (DF)
    WAYNE, AS
    ROSENBLUM, ND
    SALLAN, D
    RINK, LM
    DAVIES, KJ
    PEARSON, HA
    BLOOD, 1993, 82 (10) : A476 - A476
12345